Development and Validation of a UHPLC-MS/MS Method for the Simultaneous Quantification of Candesartan and Bisoprolol Together with Other 16 Antihypertensive Drugs in Plasma Samples

Antihypertensive pharmacological therapy is often characterized by a coadministration of different classes of drugs. Therefore, analytical methods allowing the simultaneous quantification of many drugs are needed for therapeutic drug monitoring (TDM) purposes in this context. In particular, TDM repr...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 67; no. 24; pp. 22124 - 22133
Main Authors Palermiti, Alice, De Nicolò, Amedeo, Manca, Alessandra, Antonucci, Miriam, Mula, Jacopo, Billi, Martina, Cusato, Jessica, Carta, Alessandro, Pappaccogli, Marco, Ponsa, Lara, Fasano, Chiara, De Rosa, Francesco Giuseppe, Rabbia, Franco, Veglio, Franco, D’Avolio, Antonio
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 26.12.2024
Subjects
Online AccessGet full text
ISSN0022-2623
1520-4804
1520-4804
DOI10.1021/acs.jmedchem.4c02045

Cover

More Information
Summary:Antihypertensive pharmacological therapy is often characterized by a coadministration of different classes of drugs. Therefore, analytical methods allowing the simultaneous quantification of many drugs are needed for therapeutic drug monitoring (TDM) purposes in this context. In particular, TDM represents a useful tool to discriminate poor adherence from real cases of resistant hypertension. For this reason, the aim of this study is to validate, following the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) guidelines, an ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous quantification of 18 antihypertensive drugs in human plasma. A LX-50 coupled with a QSight 220 UHPLC-MS/MS system with electrospray ionization and multiple reaction monitoring mode was used, after a binary gradient separation (13 min) on a reverse-phase Acquity UPLC HSS T3 [1.8 μm, 2.1 mm × 150 mm] column. Method validation showed a stable and acceptable matrix effect, recovery, high accuracy, and precision, assessing the eligibility of this method for routine use in the clinical context.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0022-2623
1520-4804
1520-4804
DOI:10.1021/acs.jmedchem.4c02045